C4X Discovery Holdings says it is on course to become a self-sustaining drugs discovery 'engine'
Its high-value, pre-clinical portfolio has been developed to generate licensing deals
Company
C4X Discovery Holdings PLC
LON:C4XD
C4X Discovery Holdings PLC is a pioneering drug discovery company combining scientific expertise with cutting-edge drug discovery technologies to efficiently deliver world leading medicines. The company has a highly valuable and differentiated approach to drug discovery through its enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. C4X Discovery's commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage drug discovery programmes ready for out-licensing to partners and it has two commercially partnered programmes with one candidate in clinical development.
96 stories · page 5 of 5
FTSE 100 closes lower as traders mull ECB policy
The FTSE 100 closed at 7,237 as the European Central Bank announced its latest policy decision
Archive
BHP Billiton and banks dominate big week for blue chips
Week ahead: Huge for blue chip announcements with four high street banks, the UK’s two pharma giants, mining titans Anglo and BHP and restaurant to coffee chain Whitbread just a few of those updating.
C4X to raise up to £7mln through a share placing
The company is looking to complete at least one revenue-generating deal on the C4XD portfolio in the next 12 months
Results light up LED group ProPhotonix
Risers and fallers in London at 3,30pm: Prophotonix, Interquest, Surgical Innovations
FTSE shares end lower as sterling marks 8-week low vs dollar on Brexit jitters
FTSE 100 shares closed lower on Tuesday after investors turned edgy over Brexit plans which hit banking and retail shares as well as took sterling to an 8-week low against the US dollar
Archive
Proactive news round-up: Satellite Solutions Worldwide, C4X Discovery, Tissue Regenix …
A glance at some of the stories on the Proactive newswire today
C4X Discovery to focus on early stage licensing deals
From its initial float in 2014, the firm has grown three drug programmes to now eight programmes
Archive
Day Ahead: US jobs data to dominate in absence of corporate news
After US jobs growth of 178,000 in November, market expectations are for the increase in non-farm payrolls to come in at around 160,000 for December.
Investments and investor services
Week Ahead: Next PLC feeling the chill
Happy New Year, Proactive people! That's 2016 done with; Next!
Archive
Proactive news round-up: Breedon Aggregates, C4X Discovery, Advanced Oncotherapy..
A glance at some of the headlines on the Proactive newswire today
C4X raising £5mln to power drug discovery engine
“The completion of this fundraise will allow C4XD to continue on its path to becoming the world's most productive drug discovery engine."
C4X Discovery's bargain buy boosts its drug-finding software
Drug discovery company snaps up software system for "non-material" sum
C4X Discovery acquires new technology
It said it paid a “non-material amount” for the platform, which complements its Conformetrix technology.
C4X Discovery reports drug development progress
Group said its technology had highlighted new areas for potential drug development
C4X Discovery up research spending as programme progresses
C4X has an an ambition to increase the number of pipeline programmes more than threefold by 2019